相似文献
1
Structural basis of respiratory syncytial virus neutralization by motavizumab.
Nat Struct Mol Biol. 2010 Feb;17(2):248-50. doi: 10.1038/nsmb.1723. Epub 2010 Jan 24.
2
Evaluation of a synthetic peptide as a replacement for the recombinant fusion protein of respiratory syncytial virus in a potency ELISA.
J Pharm Biomed Anal. 2011 Feb 20;54(3):572-6. doi: 10.1016/j.jpba.2010.09.008. Epub 2010 Sep 16.
3
Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.
Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):E6849-E6858. doi: 10.1073/pnas.1609449113. Epub 2016 Oct 17.
4
Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus.
Nat Microbiol. 2017 Jan 30;2:16272. doi: 10.1038/nmicrobiol.2016.272.
5
Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater Protection than the Murine Precursor of Palivizumab.
J Virol. 2017 Jul 12;91(15). doi: 10.1128/JVI.00176-17. Print 2017 Aug 1.
6
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.
Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9619-24. doi: 10.1073/pnas.1106536108. Epub 2011 May 17.
7
Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes.
J Virol. 2020 Feb 28;94(6). doi: 10.1128/JVI.01879-19.
8
Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes.
J Virol. 2011 Aug;85(15):7788-96. doi: 10.1128/JVI.00555-11. Epub 2011 May 25.
9
Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.
Virology. 2014 Apr;454-455:139-44. doi: 10.1016/j.virol.2014.02.010. Epub 2014 Mar 3.
10
A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein.
Nat Microbiol. 2017 Jan 30;2:16271. doi: 10.1038/nmicrobiol.2016.271.
引用本文的文献
1
Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance Profiles.
Viruses. 2025 May 30;17(6):793. doi: 10.3390/v17060793.
2
A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus.
Nat Commun. 2025 Feb 5;16(1):1386. doi: 10.1038/s41467-025-56302-1.
3
DS2 designer pre-fusion F vaccine induces strong and protective antibody response against RSV infection.
NPJ Vaccines. 2024 Dec 31;9(1):258. doi: 10.1038/s41541-024-01059-9.
4
A potent broad-spectrum neutralizing antibody targeting a conserved region of the prefusion RSV F protein.
Nat Commun. 2024 Nov 21;15(1):10085. doi: 10.1038/s41467-024-54384-x.
5
Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus.
Nat Commun. 2024 Nov 16;15(1):9939. doi: 10.1038/s41467-024-54287-x.
6
Prevention of respiratory syncytial virus from 1991 to 2024: a systematic review and bibliometrics analysis.
Transl Pediatr. 2024 Oct 1;13(10):1858-1869. doi: 10.21037/tp-24-271. Epub 2024 Oct 28.
7
The Cumulative Variations of Respiratory Syncytial Virus Fusion Protein (F) in Ten Consecutive Years in China.
Infect Dis Rep. 2024 Oct 17;16(5):1017-1029. doi: 10.3390/idr16050081.
8
Global progress in clinical research on human respiratory syncytial virus vaccines.
Front Microbiol. 2024 Sep 2;15:1457703. doi: 10.3389/fmicb.2024.1457703. eCollection 2024.
9
Genomic characterization of human respiratory syncytial virus circulating in Islamabad, Pakistan, during an outbreak in 2022-2023.
Arch Virol. 2024 Apr 22;169(5):106. doi: 10.1007/s00705-024-06036-0.
10
A tale of two fusion proteins: understanding the metastability of human respiratory syncytial virus and metapneumovirus and implications for rational design of uncleaved prefusion-closed trimers.
bioRxiv. 2024 Mar 8:2024.03.07.583986. doi: 10.1101/2024.03.07.583986.
本文引用的文献
1
Molecular architecture of native HIV-1 gp120 trimers.
Nature. 2008 Sep 4;455(7209):109-13. doi: 10.1038/nature07159. Epub 2008 Jul 30.
2
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins.
Nat Struct Mol Biol. 2008 Mar;15(3):312-7. doi: 10.1038/nsmb.1382. Epub 2008 Feb 10.
3
Inference of macromolecular assemblies from crystalline state.
J Mol Biol. 2007 Sep 21;372(3):774-97. doi: 10.1016/j.jmb.2007.05.022. Epub 2007 May 13.
4
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
J Mol Biol. 2007 May 4;368(3):652-65. doi: 10.1016/j.jmb.2007.02.024. Epub 2007 Feb 20.
5
Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation.
Nature. 2006 Jan 5;439(7072):38-44. doi: 10.1038/nature04322.
6
Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.
J Mol Biol. 2005 Jul 1;350(1):126-44. doi: 10.1016/j.jmb.2005.04.049.
7
Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants.
J Infect Dis. 2004 Dec 1;190(11):1941-6. doi: 10.1086/425515. Epub 2004 Oct 27.
8
Modelling the structure of the fusion protein from human respiratory syncytial virus.
Protein Eng. 2002 May;15(5):365-71. doi: 10.1093/protein/15.5.365.
9
10
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.
J Infect Dis. 1997 Nov;176(5):1215-24. doi: 10.1086/514115.
Zotero 插件